Analyst Ratings For Axovant Sciences Ltd (NYSE:AXON)
Today, Axovant Sciences Ltd (NYSE:AXON) stock was downgraded by Piper Jaffray Companies from Overweight to Neutral.
There are 2 sell ratings, 9 buy ratings on the stock.
The current consensus rating on Axovant Sciences Ltd (NYSE:AXON) is Buy (Score: 2.64) with a consensus target price of $27.15 per share, a potential 8.77% upside.
Some recent analyst ratings include
- 9/26/2017-Piper Jaffray Companies was Downgraded by analysts at Piper Jaffray Companies from a “Overweight ” rating to a ” Neutral” rating.
- 9/26/2017-Robert W. Baird was Downgraded by analysts at Robert W. Baird from a “Outperform ” rating to a ” Neutral” rating.
- 9/25/2017-Oppenheimer Holdings, Inc. Reiterated Rating of Buy.
- 9/23/2017-Chardan Capital Reiterated Rating of Sell .
- 9/8/2017-Evercore ISI initiated coverage with a Outperform rating.
- 6/21/2017-Cowen and Company Reiterated Rating of Outperform.
- On 4/17/2017 David Hung, Insider, bought 539,375 with an average share price of $18.54 per share and the total transaction amounting to $10,000,012.50. View SEC Filing
- On 4/17/2017 W Anthony Vernon, Director, bought 53,937 with an average share price of $18.54 per share and the total transaction amounting to $999,991.98. View SEC Filing
- On 3/10/2016 Mark Altmeyer, Insider, bought 2,300 with an average share price of $11.14 per share and the total transaction amounting to $25,622.00. View SEC Filing
Recent Trading Activity for Axovant Sciences Ltd (NYSE:AXON)
Shares of Axovant Sciences Ltd closed the previous trading session at with shares trading hands.
